The Pharmaceutical Research and Manufacturers of America (PhRMA) this week announced the election of four new members to its board of directors.


Pharmaceutical Research and Manufacturers of America, PhRMA, board members, board of directors, Ian Read, Pfizer, Jerzy Gruhn, Novo Nordisk, Mark Iwicki, Sunovion Pharmaceuticals, Sepracor, Staffan Schubery, Lundbeck, John Castellani, pharmaceutical, biopharmaceutical, Jeffrey Kindler


















































































































































































































INSIDE THIS ISSUE
News
Opinion
Other Services
Reprints / E-Prints
Submit News
White Papers

Supplier News Breaks Archives

PhRMA elects new board members

December 21st, 2010

WASHINGTON – The Pharmaceutical Research and Manufacturers of America (PhRMA) this week announced the election of four new members to its board of directors.

PhRMA said Tuesday that the new board members are Ian Read, president and chief executive officer of Pfizer Inc.; Jerzy Gruhn, president Novo Nordisk Inc.; Mark Iwicki, president and chief operating officer of Sunovion Pharmaceuticals Inc.; and Staffan Schuberg, president of Lundbeck Inc.

"We are pleased to welcome four new biopharmaceutical heavyweights to join PhRMA's Board of Directors," John Castellani, president and CEO of PhRMA, said in a statement. "As leaders of one of the most research-intensive sectors in the U.S., they bring to the table incredible insight and a keen understanding of the challenging economic, legislative and regulatory environments the industry faces on a daily basis."

Castellani added, "Despite these challenges, our board of directors has made it a top priority to build upon core patient-centered principles that guide our advocacy efforts as we work to advance public policies that foster medical innovation and help the U.S. maintain its global leadership in medical discovery. We look forward to working with all our board members to this aim in the months and years ahead."

Three of the four new board members assumed their current positions at their companies only recently.

Read was named president and CEO at Pfizer earlier this month, following the retirement of Jeffrey Kindler. Schuberg took the role of president at Lundbeck in November, and Iwicki was promoted to president and COO of Sepracor, now Sunovion Pharmaceuticals, in February 2010. Gruhn also serves as senior vice president of Novo Nordisk North America, having joined the U.S. business in 2008.

Advertisement